Regeneron Pharma (REGN) PT Raised to $875 at Evercore ISI

Evercore ISI analyst Cory Kasimov raised the price target on Regeneron Pharma (NASDAQ: REGN) to $875.00 (from $750.00) while maintaining a Outperform rating.

The analyst comments "We’ve refreshed our model following JPM’s Eylea preannouncement, price increases, & our latest views on the pipeline. We remain constructive on REGN given Dupixent’s continued growth trajectory & Eylea HD being close to checking all the necessary boxes to compete more effectively (PFS 2Q26). Although we acknowledge a lack of NT catalysts (besides LAG-3), we believe there are several areas of the story that remain underappreciated by the Street including C5, obesity, and Factor XI. Reit OP, PT to $875."

You May Also Be Interested In

• Raymond James Starts SpyGlass Pharma (SGP) at Outperform
• Citi raises EquipmentShare price target to $22, keeps Neutral
• Braze Inc (BRZE) PT Raised to $35 at BTIG